Tolvaptan: all 90 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)RecruitingNCT04782258Phase 3
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume OverloadCompletedNCT03255226Phase 3Results posted
- A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADHCompletedNCT03048747Phase 3Results posted
- A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male SubjectsCompletedNCT02994394Phase 1Results posted
- Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)CompletedNCT02964273Phase 3Results posted
- Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart FailureCompletedNCT02606253Phase 4Results posted
- TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot StudyCompletedNCT02538016Not applicableResults posted
- Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying RespondersCompletedNCT02476409Phase 4Results posted
- International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic HyponatremiaCompletedNCT02449044Phase 3Results posted
- A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or HemodiafiltrationCompletedNCT02331680Phase 2Results posted
- Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02251275Phase 3Results posted
- Aquaresis Utility for Hyponatremic Acute Heart Failure StudyCompletedNCT02183792Phase 4Results posted
- Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02160145Phase 3Results posted
- An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic HyponatremiaTerminatedNCT02020278Phase 3Results posted
- Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic HyponatremiaTerminatedNCT02012959Phase 3Results posted
- A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)CompletedNCT02009878Phase 1/2Results posted
- Effects of Tolvaptan in Healthy AdultsCompletedNCT01973140Phase 4Results posted
- Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal DialysisCompletedNCT01895322Phase 2Results posted
- Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and HyponatremiaTerminatedNCT01890694Phase 4Results posted
- A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or HemodiafiltrationCompletedNCT01876381Phase 2Results posted
- A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)CompletedNCT01684202Phase 2Results posted
- Targeting Acute Congestion With Tolvaptan in Congestive Heart FailureCompletedNCT01644331Phase 3Results posted
- 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2Results posted
- Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure PatientsCompletedNCT01439009Phase 4Results posted
- Pilot Study of Using Copeptin to Predict Response to TolvaptanCompletedNCT01346072Phase 4Results posted
- Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01336972Phase 2Results posted
- Tolvaptan for Ascites in Cirrhotic PatientsCompletedNCT01292304Phase 4Results posted
- A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3Results posted
- Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional HyponatremiaTerminatedNCT01227512Phase 3Results posted
- Tolvaptan Extension Study in Participants With ADPKDCompletedNCT01214421Phase 3Results posted
- Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDCompletedNCT01210560Phase 2Results posted
- Tolvaptan in Hyponatremic Cancer PatientsCompletedNCT01199198Phase 4Results posted
- A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic EdemaCompletedNCT01114828Phase 3Results posted
- A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic EdemaCompletedNCT01050530Phase 3Results posted
- A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mgCompletedNCT01048788Phase 3Results posted
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3Results posted
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]CompletedNCT00841568Phase 2Results posted
- Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic PatientsCompletedNCT00550459Phase 3Results posted
- A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)CompletedNCT00544869Phase 3Results posted
- A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)CompletedNCT00525265Phase 3Results posted
- A Dose-defining Study of OPC-41061 in Treatment of Hepatic EdemaCompletedNCT00479336Phase 2Results posted
- A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)CompletedNCT00462670Phase 3Results posted
- Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00428948Phase 3Results posted
- Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00413777Phase 2Results posted
- A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)CompletedNCT00234104Phase 2Results posted
- Phase I Study Multi Dose of 7.5mg Tolvaptan in Health MaleCompletedNCT07166887Phase 1
- Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial ProtocolCompletedNCT07166783Phase 1
- A Study of HRS-9057 in Patients With Heart Failure and Volume OverloadCompletedNCT06506994Phase 1
- Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAHStatus unknownNCT05569655Not applicable
- A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)WithdrawnNCT04786574Phase 3
- Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal DysfunctionStatus unknownNCT04331132Not applicable
- Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney DiseaseCompletedNCT03949894Phase 4
- Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)Status unknownNCT03931369Phase 2
- The Role of Vasopressin Antagonism on Renal Sodium HandlingCompletedNCT03910231Phase 1
- Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKDCompletedNCT03803124Phase 3
- Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT03596957Phase 4
- Tolvaptan-Octreotide LAR Combination in ADPKDCompletedNCT03541447Phase 2
- Tolvaptan for Advanced or Refractory Heart FailureTerminatedNCT02959411Phase 4
- Efficacy of Tolvaptan on ADPKD PatientsStatus unknownNCT02729662Not applicable
- Regional Tolvaptan RegistryStatus unknownNCT02666651Phase 4
- AiDing Diuresis wIth Tolvaptan (ADD-IT)CompletedNCT02646540Phase 1
- The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves ReplacementCompletedNCT02644616Phase 4
- Tolvaptan for Patients With Acute Neurological InjuriesTerminatedNCT02545114Not applicable
- Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemCompletedNCT02527863Phase 2
- A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic HyponatremiaWithdrawnNCT02442674Phase 3
- Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart FailureTerminatedNCT02352285Phase 4
- Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent AscitesCompletedNCT02173288Phase 2/3
- Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle StudyCompletedNCT02096965Phase 1
- Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)CompletedNCT02078973Phase 2
- Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)WithdrawnNCT01733134Phase 3
- Tolvaptan for Hyponatremia in Cirrhotic Patients With AscitesStatus unknownNCT01716611Phase 4
- The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot StudyWithdrawnNCT01663662Phase 4
- Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac EdemaCompletedNCT01651156Phase 3
- Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)CompletedNCT01638663Phase 2
- Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart FailureCompletedNCT01618448Phase 3
- Effect of Tolvaptan on Cognitive Function in CirrhosisCompletedNCT01556646Phase 3
- Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With AscitesTerminatedNCT01552590Phase 4
- Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute HyponatremiaStatus unknownNCT01507727Phase 2/3
- Tolvaptan for In-hospital HyponatremiaTerminatedNCT01386372Phase 2
- Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With HepatocirrhosisCompletedNCT01359462Phase 1
- Phase III Study of Tolvaptan Tablet to Treat Cirrhosis AscitesCompletedNCT01349348Phase 3
- Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With AscitesCompletedNCT01349335Phase 2
- Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed IntactCompletedNCT01261481Phase 1
- A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute HyponatremiaCompletedNCT00664014Phase 2
- Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00201994Phase 3
- Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart FailureCompletedNCT00132886Phase 2
- "SALT Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00072683Phase 3
- EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With TolvaptanCompletedNCT00071331Phase 3
- Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure PatientsCompletedNCT00043771Phase 2
- Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure PatientsCompletedNCT00043758Phase 2